Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium
- PMID: 20392870
- PMCID: PMC2902068
- DOI: 10.1210/jc.2009-2464
Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium
Abstract
Context: Hypoparathyroidism is among the few hormonal insufficiency states not treated with replacement of the missing hormone. This is the first randomized controlled study in children comparing treatment with synthetic human PTH 1-34 and calcitriol.
Objective: The primary objective was to assess the efficacy and safety of long-term PTH 1-34 vs. calcitriol treatment in the maintenance of normal serum calcium values and renal calcium excretion in children with hypoparathyroidism.
Setting: The study was conducted at a clinical research center.
Subjects: Subjects included 12 children aged 5-14 yr with chronic hypoparathyroidism and without severe renal or hepatic insufficiency.
Study design: The study was a 3-yr randomized parallel trial comparing twice-daily calcitriol (plus calcium and cholecalciferol in four daily doses) vs. s.c. PTH 1-34 treatment, with weekly or biweekly monitoring of serum and urine calcium.
Results: Mean predose serum calcium levels were maintained at, or just below, the normal range, and urine calcium levels remained in the normal range throughout the 3-yr study, with no significant differences between treatment groups. Creatinine clearance, corrected for body surface area, did not differ between groups and remained normal throughout the study. Markers of bone turnover were mildly elevated during PTH 1-34 therapy and remained within the normal range during calcitriol therapy. Mean bone mineral density Z-scores at the anterior-posterior lumbar spine, femoral neck, distal radius, and whole body remained within the normal range and did not differ between groups throughout the study. Similarly, height and weight percentiles did not differ between treatment groups and remained normal throughout the 3-yr follow-up.
Conclusion: We conclude that PTH 1-34 therapy is safe and effective in maintaining stable calcium homeostasis in children with hypoparathyroidism. Additionally, PTH 1-34 treatment allowed normal skeletal development because there were no differences in bone mineral accrual, linear growth, or weight gain between the two treatment arms over the 3-yr study period.
Figures
Similar articles
-
Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium.J Clin Endocrinol Metab. 2003 Sep;88(9):4214-20. doi: 10.1210/jc.2002-021736. J Clin Endocrinol Metab. 2003. PMID: 12970289 Clinical Trial.
-
Long-Term Parathyroid Hormone 1-34 Replacement Therapy in Children with Hypoparathyroidism.J Pediatr. 2018 Dec;203:391-399.e1. doi: 10.1016/j.jpeds.2018.08.010. J Pediatr. 2018. PMID: 30470382 Free PMC article.
-
Therapy of Hypoparathyroidism With PTH(1-84): A Prospective Six Year Investigation of Efficacy and Safety.J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50. doi: 10.1210/jc.2015-4135. Epub 2016 May 4. J Clin Endocrinol Metab. 2016. PMID: 27144931 Free PMC article. Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Advances in the treatment of hypoparathyroidism with PTH 1-34.Bone. 2019 Mar;120:535-541. doi: 10.1016/j.bone.2018.09.018. Epub 2018 Sep 21. Bone. 2019. PMID: 30243992 Review.
Cited by
-
Hypoparathyroidism: an update on new therapeutic approaches.Endocrine. 2024 Oct 13. doi: 10.1007/s12020-024-04057-y. Online ahead of print. Endocrine. 2024. PMID: 39397231 Review.
-
Recombinant PTH Infusion in a Child With Sanjad-Sakati Syndrome Refractory to Conventional Therapy.JCEM Case Rep. 2024 Apr 23;2(4):luae059. doi: 10.1210/jcemcr/luae059. eCollection 2024 Apr. JCEM Case Rep. 2024. PMID: 38655381 Free PMC article.
-
Transitory Activation and Improved Transition from Erosion to Formation within Intracortical Bone Remodeling in Hypoparathyroid Patients Treated with rhPTH(1-84).JBMR Plus. 2023 Nov 17;7(12):e10829. doi: 10.1002/jbm4.10829. eCollection 2023 Dec. JBMR Plus. 2023. PMID: 38130746 Free PMC article. Clinical Trial.
-
Assessment of quality of life in patients with permanent hypoparathyroidism receiving conventional treatment.J Diabetes Metab Disord. 2023 Sep 15;22(2):1617-1623. doi: 10.1007/s40200-023-01292-4. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975128 Free PMC article.
-
Treatment options in hypoparathyroidism.Arch Endocrinol Metab. 2022 Nov 11;66(5):651-657. doi: 10.20945/2359-3997000000554. Arch Endocrinol Metab. 2022. PMID: 36382754 Free PMC article. Review.
References
-
- Weber G, Cazzuffi MA, Frisone F, de Angelis M, Pasolini D, Tomaselli V, Chiumello G 1988–1989 Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydrocholecalciferol. Child Nephrol Urol 9:273–276 - PubMed
-
- Santos F, Smith MJ, Chan JC 1986 Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D). Am J Dis Child 140:139–142 - PubMed
-
- Strögmann W, Bohrn E, Woloszezuk W 1990 First experiences in the substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone. Monatsschr Kinderheilkd 138:141–146 - PubMed
-
- Winer K, Yanovski JA, Cutler Jr GB 1996 Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. JAMA 276:631–636 - PubMed
-
- Winer KK, Yanovski JA, Sarani B, Cutler Jr GB 1998 A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480–3486 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources